Shire sues Amneal over proposed generic Lialda
Drug maker Shire, alongside two other companies, has sued Amneal Pharmaceuticals for allegedly infringing a patent related to Lialda, a drug for treating ulcerative colitis.
Biotechs 'concerned' by Dutch plans for plant breeders
Biotechnology companies are concerned about the Dutch government’s plans to allow small plant breeders to develop new breeds while avoiding paying licensing fees, according to reports.
Teva bids $40bn for Mylan
Pharmaceutical company Teva has offered to buy fellow drug maker Mylan in a deal that could be worth $40 billion.
Canada’s Supreme Court throws out Sanofi compensation appeal
The Supreme Court of Canada has dismissed an appeal by French pharmaceutical company Sanofi in its patent dispute with Canadian generic drug maker Apotex.
Kyle Bass launches IPR challenge against Imbruvica patent
Texas hedge fund manager Kyle Bass has sought another inter partes review, this time to challenge a patent covering Pharmacyclics’ cancer drug Imbruvica.
Claris Lifesciences settles propofol patent litigation with Fresenius Kabi
Healthcare company Fresenius Kabi and India-based generic drug maker Claris Lifesciences have settled their patent dispute, ending pending litigation.
Taylor Wessing promotes two life sciences lawyers
Law firm Taylor Wessing has promoted senior associates Matt Royle and Ed Vickers to partner and senior counsel, respectively.
Mylan head dismisses Teva merger
Mylan’s executive chairman Robert Coury has issued a statement confirming that his company and Teva will not merge.
Allergan sued for promoting off-label Botox use
An Ontario-based company has sued Allergan for allegedly infringing a method patent that protects the use of cosmetic drug Botox to treat back pain.
Schiff Hardin hires life sciences specialist
Law firm Schiff Hardin has added a life sciences specialist as a partner in its intellectual property group.
